Acute Alteration in Bone Mineral Density and Biochemical Markers for Bone Metabolism in Nephrotic Patients Receiving High-Dose Glucocorticoid and One-Cycle Etidronate Therapy
Abstract:It is widely known that glucocorticoids induce and accelerate osteoporosis. High-dose glucocorticoids are administrated daily to patients in the acute phase of nephrotic syndrome. It could be inferred that high-dose glucocorticoids rapidly decrease patients' basal bone mineral density (BMD) and this accelerates the natural progress of osteoporosis associated with aging or menopause. Nine nephrotic patients (male/female: 5/4) without previous prednisolone administration were chosen to measure BMD and the level … Show more
“…After a median of 18 days following GC initiation, every 1 mg/m 2 increase in GC therapy (prednisone equivalents) was associated with a decrease in spine BMD Z-score of almost 0.4 standard deviation (SD). This finding was consistent with a recent report in adult GC-treated NS in which significant declines in spine BMD Z-scores were evident after just 12 weeks of GC therapy [10]. Similarly, a large cross-sectional case-control study showed lower spine bone mineral content after 4 years of GC exposure in children with steroid-sensitive NS, suggesting the potential for residual bone mass deficits in the longer term [11].…”
Section: Introductionsupporting
confidence: 92%
“…A number of studies have shown a significant decrease in LS BMD Z-scores in the first few weeks of GC therapy, both in children [36] and in adults [10] with NS. These observations are attributable to the acute effects of GC on bone, as demonstrated in animal models [37], and on trans-iliac bone specimens from adults [38].…”
Introduction-Vertebral fracture (VF) incidence following glucocorticoid (GC) initiation has not been previously reported in pediatric nephrotic syndrome.
“…After a median of 18 days following GC initiation, every 1 mg/m 2 increase in GC therapy (prednisone equivalents) was associated with a decrease in spine BMD Z-score of almost 0.4 standard deviation (SD). This finding was consistent with a recent report in adult GC-treated NS in which significant declines in spine BMD Z-scores were evident after just 12 weeks of GC therapy [10]. Similarly, a large cross-sectional case-control study showed lower spine bone mineral content after 4 years of GC exposure in children with steroid-sensitive NS, suggesting the potential for residual bone mass deficits in the longer term [11].…”
Section: Introductionsupporting
confidence: 92%
“…A number of studies have shown a significant decrease in LS BMD Z-scores in the first few weeks of GC therapy, both in children [36] and in adults [10] with NS. These observations are attributable to the acute effects of GC on bone, as demonstrated in animal models [37], and on trans-iliac bone specimens from adults [38].…”
Introduction-Vertebral fracture (VF) incidence following glucocorticoid (GC) initiation has not been previously reported in pediatric nephrotic syndrome.
“…First, it is well-known that GCs have a predilection for interference with trabecular bone architecture, both in humans [6] and in animal models [5]. Furthermore, bone resorption markers increase acutely in adults with NS following administration of GCs [28], and are associated with a significant decline in spine BMD after a few weeks of therapy in both adults [28] and children with NS [9]. In addition, spine BMD has been shown to decline rapidly in adults following GC initiation for organ transplantation [29].…”
Introduction-Vertebral fractures are an under-recognized complication of childhood glucocorticoid-treated illnesses. Our goal was to study the relationship among glucocorticoid exposure, lumbar spine areal BMD (LS BMD) and vertebral shape in glucocorticoid-treated children with new-onset nephrotic syndrome.
“…Figure 4 shows the bone loss from the spine of first-time user followed in longitudinal studies [9,20,25,33,38,42,51,56,67,71]. One limitation of evaluating bone loss longitudinally is that daily dose may vary and reduce over time.…”
Abstract. Studies of oral corticosteroid dose and loss of bone mineral density have reported inconsistent results. In this meta-analysis, we used information from 66 papers on bone density and 23 papers on fractures to examine the effects of oral corticosteroids on bone mineral density and risk of fracture. Strong correlations were found between cumulative dose and loss of bone mineral density and between daily dose and risk of fracture. The risk of fracture was found to increase rapidly after the start of oral corticosteroid therapy (within 3 to 6 months) and decrease after stopping therapy. The risk remained independent of underlying disease, age and gender. We conclude that oral corticosteroid treatment using more than 5 mg (of prednisolone or equivalent) daily leads to a reduction in bone mineral density and a rapid increase in the risk of fracture during the treatment period. Early use of preventive measures against corticosteroid-induced osteoporosis is recommended.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.